Metsera, A Wholly Owned Subsidiary Of Pfizer
Clinical trials sponsored by Metsera, A Wholly Owned Subsidiary Of Pfizer, explained in plain language.
-
Early trial tests new drug duo for weight loss
Disease control Recruiting nowThis early-stage study is testing the safety and effects of two experimental drugs, MET233 and MET097, given together as weekly injections. It aims to see if this combination helps adults with obesity or overweight lose weight, including some participants who also have type 2 dia…
Phase: PHASE1, PHASE2 • Sponsor: Metsera, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Major trial tests new weekly shot to fight obesity
Disease control Recruiting nowThis study is testing a new weekly injection called MET097 to see how well it helps people with obesity or overweight lose weight and improve related health measures. It will involve about 3,500 adults who have weight-related health issues like high blood pressure or sleep apnea,…
Phase: PHASE3 • Sponsor: Metsera, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC